Sanofi SA

SNY

Company Profile

  • Business description

    Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.

  • Contact

    46, Avenue de la Great Army
    Paris75017
    FRA

    T: +33 153774000

    E: [email protected]

    https://www.sanofi.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2026

    Employees

    74,846

Sanofi SA News & Analysis

stocks

10 best US blue-chip stocks to buy for the long term

The stocks of these high-quality companies with large market capitalisations look undervalued today.
personal-finance

Can you achieve global diversification with multinational companies?

A Morningstar report explores if the benefits of global investing can be achieved by investing in global companies trading on local exchanges.
stocks

Magnificent Seven vs. the ‘Granolas’: How does Europe’s version stack up?

‘Granolas’ stocks are profitable, diversified, cheap—and posting big returns.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,093.4013.60-0.15%
CAC 408,259.6013.810.17%
DAX 4023,803.953.04-0.01%
Dow JONES (US)47,916.57269.23-0.56%
FTSE 10010,600.532.95-0.03%
HKSE25,587.26306.28-1.18%
NASDAQ22,902.8980.480.35%
Nikkei 22556,282.79641.32-1.13%
NZX 50 Index12,989.56191.88-1.46%
S&P 5006,816.897.77-0.11%
S&P/ASX 2008,907.004.80-0.05%
SSE Composite Index3,979.266.96-0.17%

Market Movers